02615 百利天恒
BIOKIN
BIOKIN
| Register Close | 2025/11/12 IPO Closing in 4 Days |
| Listing Date | 2025/11/17 |
|
|
|
|
|
|
|
|
|
|
IPO Detail
COMPANY PROFILE
Sichuan Biokin Pharmaceutical Co. is an integrated pharmaceutical group with capabilities spanning early-stage research and development, clinical development, manufacturing and commercialization. The Group operated two major businesses: innovative biologics business, and generics and traditional Chinese medicine business.
--
In 2014, the Group established SystImmune in Seattle, U.S., embarking on the development of iza-bren (BL-B01D1), the world’s first and only EGFR × HER3 bispecific ADC to have entered into Phase III clinical development to date. In 2024, the Group entered into a global strategic license and collaboration agreement for iza-bren with BMS, with a US$800 million upfront payment and a total deal value worth up to US$8.4 billion — being the largest ever for a single-asset collaboration transaction in the ADC space in terms of total deal value.
--
The Group generated revenue from the sales of 31 approved drug products with over 100 specifications, which includes 26 generics products and five traditional Chinese medicine products. As of October 31, 2025, all of the Group’s innovative drug candidates remained new drug application, in clinical or preclinical development stage.
BASIC INFORMATION
| Market | Hong Kong (Main Board) |
| Business Nature | Health Care |
| Major Business Area | China |
| Board Lot | 100 |
GLOBAL OFFERING
| No. of Offer Shares | 8.63M H shares |
| No. of International Offer Shares | 7.77M H shares |
| No. of HK Offer Shares | 0.86M H shares |
| Offer Price | $347.50 - $389.00 |
| Stock Code | 2615 |
| Sponsor(s) | Goldman Sachs (Asia) L.L.C., J.P. Morgan Securities (Far East) Limited, CITIC Securities (Hong Kong) Limited |
| Underwriter(s) | Goldman Sachs (Asia) L.L.C., J.P. Morgan Securities (Asia Pacific) Limited, CLSA Limited, SDICS International Securities (Hong Kong) Limited |
TIME TABLE
| Application Period | Nov 07 (Fri) - noon, Nov 12 (Wed) |
| Price Determination Date | Nov 13 (Thu) |
| Result Announcement Date | On or before Nov 14 (Fri) |
| Result Announcement Date | On or before Nov 14 (Fri) |
| Result Announcement Date | On or before Nov 17 (Mon) |
| Dealings in Shares commence on | Nov 17, 2025. (Mon) |
Reallocation of Shares Offered
Sales Statistics (HKD)
| Offer Price | $347.50 - $389.00 |
| Capitalization (H Shares) | 3.00B - 3.36B |
| NAV / share ($) | $14.3 - $15.1 (Unaudited pro forma adj NAV / share) |
Use Of Proceeds
| Assuming the offer price being at HKD 368.25, the net proceeds raised would be HKD 3.02B, of which |
| -- |
| -- |
| -- |
Related Document
| Prospectus |  Chinese Version | English Version |
| Remark： | The above information is referenced from the prospectus. |
| All data is calculated from the non- exercise rights(if applicable). |
Name︰
--
--
--
Subscription --
Result Announcement --
Listing --Offer Price︰--
| Currency | : |
| Listing Price | : |
| Board Lot | : |
| Admission Fee* |
: |
| Subscribing Lot | : |
| Subscribing Fee | : |
| Subscribing Amount | : |
*Admission fees include brokerage of 1%, SFC transaction levy of 0.0027%, Stock Exchange trading fee of 0.005% and FRC transaction levy of 0.00015% (i.e. 1.0077% in total).